PeptideStack
5.2kquestions
20kanswers
220users

semaglutide

Page 9 of 20 · 470 questions tagged semaglutide.

470 questions · sorted by votes · page 9 of 20

21 votes 4 answers22k views
Is SOUL a fair comparison of oral semaglutide against its comparator arm?

The particulars: SOUL · oral semaglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Is…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by amara_nwachukwu 20k · 13 months ago
21 votes 3 answers21k views
I want to move my injection day. How much drift does the label actually allow, and in which direction?

My weekly dose currently lands on a Thursday and that is now the worst day of my week for it. I want it on a Sunday. That is a three-day move and I can see two ways…

missed-dose
missed-dose

What the label instructions for a missed weekly dose are, why they differ between agents, and what the pharmacokinetics say about drift in an…

41 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by two_two_micron 9.3k · 14 months ago
21 votes 5 answers18k views
Why do two papers on SURPASS-3 report different headline figures?

I have the full paper rather than the abstract, and the supplementary appendix. I would like the mechanism, because I want to be able to reason about the cases nobody…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by halvard_ness 69k · 15 months ago
21 votes 5 answers15k views
Does the STEP 4 population resemble anyone asking about semaglutide here?

Conditions: STEP 4 · semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by Dr_Colm_Fitzhenry 69k · 6 months ago
21 votes5 answers14k views
If a semaglutide dose is missed by twenty-eight days, does the ladder reset?

What I have: semaglutide · twenty-eight days. I have done this once and I suspect I got away with it rather than got it right. For context: I keep records of every…

missed-dose
missed-dose

What the label instructions for a missed weekly dose are, why they differ between agents, and what the pharmacokinetics say about drift in an…

41 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by plunger_stop 13k · 18 months ago
21 votes5 answers13k views
Is 30 mg in 5 mL of sterile water for injection a sensible presentation for semaglutide?

Numbers first: 30 mg · 5 mL · sterile water for injection · semaglutide. This is a planning question. I know what my options are; I do not know how to weigh them.…

diluent-volume
diluent-volume

Choosing how much diluent to add, which is really a question about what you want your measurement resolution to be. Larger volumes buy you…

295 questions
reconstitution
reconstitution

Taking a lyophilised vial to a solution of known concentration: choice of diluent, volume selection, how to add liquid without shearing the cake,…

313 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
sterile-water
sterile-water

Preservative-free sterile water for injection: appropriate for a single-withdrawal presentation, a poor choice for anything you intend to open…

35 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by a_lindgren 58k · 6 months ago
21 votes5 answers9.6k views
Why is oral semaglutide bioavailability only about one per cent?

This matters because it predicts what a related molecule should do. This is one of those things that everyone repeats and nobody derives. This matters practically,…

oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
asked by plunger_stop 13k · 11 months ago
21 votes 3 answers7.3k views
Working the FLOW renal composite into ARR and NNT - am I doing this correctly?

FLOW tested semaglutide 1.0 mg in people with type 2 diabetes and chronic kidney disease, and reported a hazard ratio of 0.76 for its composite kidney endpoint. I…

renal-outcomes
renal-outcomes

Kidney endpoints: the FLOW composite, eGFR slope as an endpoint, albuminuria regression, and why an early eGFR dip is expected rather than alarming.

9 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
asked by esther_vandeVelde 52k · 15 months ago
21 votes3 answers6.5k views
How much of the placebo-arm result in these trials is the lifestyle intervention, and does it distort the drug effect?

I noticed that the placebo arms in this literature do not behave consistently. STEP 1 placebo loses 2.4%. STEP 3 placebo loses 5.7%. SURMOUNT-3 placebo gains 2.5%.…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
exercise
exercise

Training during substantial weight loss: cardiorespiratory work, step count, low energy availability, and how exercise interacts with the appetite…

38 questions
asked by ben_akintola 10k · 11 months ago
20 votes 5 answers25k views
Is there any published stability data for semaglutide at 2–8 °C?

The case in front of me: semaglutide · 2–8 °C. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one.…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by tobias_reint 20k · 2.0 years ago
20 votes5 answers23k views
Does fibrillation of semaglutide at room temperature show up as a loss of content or of purity?

Setup, so nobody has to ask: fibrillation · semaglutide · room temperature. I would like the mechanism, because I want to be able to reason about the cases nobody has…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by hana_petrikova 10k · 11 months ago
20 votes 5 answers22k views
Does the SURMOUNT-OSA population resemble anyone asking about a GLP-1 receptor agonist here?

Setup, so nobody has to ask: SURMOUNT-OSA · a GLP-1 receptor agonist. I have read the primary source rather than the summary, which has left me with more questions. I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by eoin_mcgarry 18k · 20 months ago
20 votes3 answers15k views
What does PIONEER-1 actually establish about oral semaglutide?

What I am working with: PIONEER-1 · oral semaglutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
asked by tamsin_wray 9.9k · 6 months ago
20 votes 5 answers15k views
Can I reconstitute semaglutide at 2 mg/mL and still measure a small dose accurately?

Conditions: semaglutide · 2 mg/mL. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the plan…

diluent-volume
diluent-volume

Choosing how much diluent to add, which is really a question about what you want your measurement resolution to be. Larger volumes buy you…

295 questions
insulin-syringe
insulin-syringe

U-100 and U-40 insulin syringes as measuring instruments. A U-100 syringe is graduated in insulin units where 100 units equals 1 mL, so one unit…

244 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by ellis_thorne 17k · 5 months ago
20 votes 5 answers14k views
Does cystatin C tell me anything about hepatic fat on semaglutide?

The specifics, since they change the answer: cystatin C · semaglutide. I understand the observation; what I do not understand is the mechanism behind it. I have read…

liver-enzymes
liver-enzymes

ALT, AST, GGT and ALP: what they do and do not indicate about hepatic fat, why enzymes are a poor surrogate for histology, and where non-invasive…

91 questions
mash
mash

Metabolic dysfunction-associated steatohepatitis: histological endpoints, resolution without worsening fibrosis, fibrosis improvement by stage,…

56 questions
bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by ten_mg_vial 31k · 8 months ago
20 votes0 answers13k views
How comparable are tirzepatide and mazdutide on the evidence available?

For reference: tirzepatide · mazdutide. I am trying to choose between two options that are usually discussed as though only one exists. I am not optimising for price,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by juan_esquivel 14k · 8 months ago
20 votes 3 answers9.5k views
Would you re-test semaglutide after four weeks at 4 °C, or accept the original certificate?

The case in front of me: semaglutide · four weeks · 4 °C. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and…

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by haze_check 9.3k · 20 months ago
20 votes4 answers7.5k views
Is semaglutide at 3.33 mg/mL stable enough for ten weeks of multi-withdrawal use?

Conditions: semaglutide · 3.33 mg/mL · ten weeks. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
bacteriostatic-water
bacteriostatic-water

Water for injection containing roughly 0.9 per cent benzyl alcohol as a bacteriostatic agent. It suppresses growth in a multiple-withdrawal vial;…

149 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by leonid_marchuk 19k · 7 months ago
20 votes 5 answers6.4k views
Why do two papers on SURPASS-2 report different headline figures?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. This is one of those things that everyone repeats and…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by colm_dunphy 8.2k · 16 days ago
20 votes 1 answer5.9k views
Is SURMOUNT-3 a fair comparison of tirzepatide against its comparator arm?

For reference: SURMOUNT-3 · tirzepatide. I would like to know whether this claim survives contact with evidence. If the answer is "nobody has tested that", I would…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by sasha_ferreira 9.4k · 5 months ago
20 votes0 answers5.6k views
What is the reported incidence of constipation on semaglutide in STEP 2?

Setup, so nobody has to ask: constipation · semaglutide · STEP 2. I have read the primary source rather than the summary, which has left me with more questions. I…

constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by fiadh_cronin 58k · 11 months ago
20 votes 2 answers4.9k views
How comparable are survodutide and liraglutide on the evidence available?

What I am working with: survodutide · liraglutide. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that,…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
asked by nadia_kowalczyk 20k · 16 days ago
19 votes5 answers32k views
Is 8 mg in 3 mL of sterile water for injection a sensible presentation for semaglutide?

Numbers first: 8 mg · 3 mL · sterile water for injection · semaglutide. This is a planning question. I know what my options are; I do not know how to weigh them. What…

diluent-volume
diluent-volume

Choosing how much diluent to add, which is really a question about what you want your measurement resolution to be. Larger volumes buy you…

295 questions
reconstitution
reconstitution

Taking a lyophilised vial to a solution of known concentration: choice of diluent, volume selection, how to add liquid without shearing the cake,…

313 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
sterile-water
sterile-water

Preservative-free sterile water for injection: appropriate for a single-withdrawal presentation, a poor choice for anything you intend to open…

35 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by lipid_panel_q 36k · 23 months ago
19 votes 5 answers28k views
Is a 31G needle the right choice for drawing semaglutide at 3.33 mg/mL?

The particulars: a 31G needle · semaglutide · 3.33 mg/mL. I am trying to choose between two options that are usually discussed as though only one exists. I am not…

needle-gauge
needle-gauge

Gauge and length selection, the trade-off between draw time and tissue trauma, coring risk with larger-bore needles, and why a fixed-needle…

91 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by tess_amankwah 22k · 2.1 years ago